AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Revenue of AVROBIO, Inc. (AVRO)
Revenue in 2023 (TTM): $
According to AVROBIO, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of AVROBIO, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-617,000 | $-71,050,000 | $12.53 M | $12.16 M |
| 2022 | $ | $-4,166,000 | $-105,434,000 | $-105,890,000 | $-106,047,000 |
| 2021 | $ | $-1,399,000 | $-118,841,000 | $-119,126,000 | $-117,727,000 |
| 2020 | $ | $-1,207,000 | $-120,228,000 | $-119,712,000 | $-118,505,000 |
| 2019 | $ | $-850,000 | $-75,809,000 | $-72,965,000 | $-72,115,000 |
| 2018 | $ | $ | $-46,243,000 | $-46,361,000 | $-46,361,000 |
| 2017 | $ | $ | $-18,041,000 | $-18,648,000 | $-18,648,000 |
| 2016 | $ | $ | $-4,586,000 | $-4,664,000 | $-4,664,000 |